Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The benefit of oral antiviral therapy in preventing hepatocellular carcinoma (HCC) in the general population is not well understood. We used a novel prediction method to estimate the risk of HCC in the Korean population based on various treatment guidelines. Methods: The 5-year risk of HCC following antiviral therapy was calculated using an HCC risk prediction model. A virtual cohort that represented Koreans (>40 years old) with chronic hepatitis B virus (HBV) infection was established using the fifth National Health and Nutrition Examination Survey. The antiviral indications tested were the Korean National Health Insurance (NHI) and European Association for the Study of the Liver (EASL) guidelines as well as a new extended indication (serum HBV DNA >2,000 IU/mL regardless of serum aminotransferase level). Results: A total of 993,872 subjects were infected with HBV in the general Korean population. Over a 5-year period, 2,725 HCC cases were predicted per 100,000 persons (0.55%/yr). When the cohort was treated based on the Korean NHI, the EASL, and the newly extended indications, HCC risks decreased to 2,531 (–7.1%), 2,089 (–23.3%), and 1,122 (–58.8%) cases per 100,000 persons, respectively (p<0.0001). Conclusions: Simulated risk prediction suggests that extending of oral antiviral indication may reduce the HCC risk in the general population.
Abstract
Background/Aims: The benefit of oral antiviral therapy in preventing hepatocellular carcinoma (HCC) in the general population is not well understood. We used a novel prediction method to estimate the risk of HCC in the Korean population based on various treatment guidelines. Methods: The 5-year risk of HCC following antiviral therapy was calculated using an HCC risk prediction model. A virtual cohort that represented Koreans (>40 years old) with chronic hepatitis B virus (HBV) infection was established using the fifth National Health and Nutrition Examination Survey. The antiviral indications tested were the Korean National Health Insurance (NHI) and European Association for the Study of the Liver (EASL) guidelines as well as a new extended indication (serum HBV DNA >2,000 IU/mL regardless of serum aminotransferase level). Results: A total of 993,872 subjects were infected with HBV in the general Korean population. Over a 5-year period, 2,725 HCC cases were predicted per 100,000 persons (0.55%/yr). When the cohort was treated based on the Korean NHI, the EASL, and the newly extended indications, HCC risks decreased to 2,531 (–7.1%), 2,089 (–23.3%), and 1,122 (–58.8%) cases per 100,000 persons, respectively (p<0.0001). Conclusions: Simulated risk prediction suggests that extending of oral antiviral indication may reduce the HCC risk in the general population.
참고문헌 (29)
- Song IH, "Current status of liver diseases in Korea: hepatocellular carcinoma", Korean J Hepatol, 15(6), pp.S50~S59 (2009)
- 김혁, "Recent trends in hepatitis B virus infection in the general Korean population", The Korean Journal of Internal Medicine, 28(4), pp.413~419 (2013), 대한내과학회[DOI]
- Report of primary liver cancer randomised registration in Korea, "Kim KS", The Korean Liver Cancer Study Group, National Cancer Registration Center (Korea), 19~ (2010)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Yang HI, "Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.1134~1143 (2008)
- Chen JD, "Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death", Gastroenterology, 138, pp.1747~1754 (2010)
- Yang HI, "Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection", J Clin Oncol, 28, pp.2437~2444 (2010)
- Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
- Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
- Gordon SC, "Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population", Clin Gastroenterol Hepatol, 12, pp.885~893 (2014)
- Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study", Gastroenterology, 147(e5), pp.143~151 (2014)
- Wong GL, "Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment", Gastroenterology, 144, pp.933~944 (2013)
- "Social security system of Korea" (2014)[URL]
- "The fifth Korean National Health and Nutrition Examination Survey" (2014)[URL]
- 이홍섭, "Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis", Clinical and Molecular Hepatology, 16(4), pp.369~375 (2010), 대한간학회
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Lee JK, "Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology", Hepatology, 51, pp.1577~1583 (2010)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Gordon SC, "Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load", Hepatology, 58, pp.505~513 (2013)
- Ridruejo E, "Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir", World J Gastroenterol, 20, pp.7169~7180 (2014)
- Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
- Heathcote EJ, "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B", Gastroenterology, 140, pp.132~143 (2011)
- Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
- Chao DT, "Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU", L and significant hepatic fibrosis, 2014, pp.39, 349~358
- Lee HW, "Prediction of development of liverrelated events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- 박보영, "Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011", Cancer Research and Treatment, 44(2), pp.113~120 (2012), 대한암학회[DOI]
- Wong CR, "Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting", Dig Dis Sci, 54, pp.2712~2721 (2009)
- Kao JH, "Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan", Intervirology, 46, pp.400~407 (2003)